JP6644678B2 - Ｃｔｌａ−４およびｃｄ４０の両方に特異的に結合可能である二重特異性分子 - Google Patents

Ｃｔｌａ−４およびｃｄ４０の両方に特異的に結合可能である二重特異性分子 Download PDF

Info

Publication number
JP6644678B2
JP6644678B2 JP2016522480A JP2016522480A JP6644678B2 JP 6644678 B2 JP6644678 B2 JP 6644678B2 JP 2016522480 A JP2016522480 A JP 2016522480A JP 2016522480 A JP2016522480 A JP 2016522480A JP 6644678 B2 JP6644678 B2 JP 6644678B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
ctla
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016522480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529215A (ja
JP2016529215A5 (enExample
Inventor
エルマーク，ピーター
フレブリング，クリスティーナ
ノーレン，パー
Original Assignee
アリゲーター バイオサイエンス アーベー
アリゲーター バイオサイエンス アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゲーター バイオサイエンス アーベー, アリゲーター バイオサイエンス アーベー filed Critical アリゲーター バイオサイエンス アーベー
Publication of JP2016529215A publication Critical patent/JP2016529215A/ja
Publication of JP2016529215A5 publication Critical patent/JP2016529215A5/ja
Application granted granted Critical
Publication of JP6644678B2 publication Critical patent/JP6644678B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016522480A 2013-06-27 2014-06-25 Ｃｔｌａ−４およびｃｄ４０の両方に特異的に結合可能である二重特異性分子 Expired - Fee Related JP6644678B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201311487A GB201311487D0 (en) 2013-06-27 2013-06-27 Bispecific molecules
GB1311487.1 2013-06-27
PCT/EP2014/063443 WO2014207064A1 (en) 2013-06-27 2014-06-25 Bispecific molecules capable of specifically binding to both ctla-4 and cd40

Publications (3)

Publication Number Publication Date
JP2016529215A JP2016529215A (ja) 2016-09-23
JP2016529215A5 JP2016529215A5 (enExample) 2017-08-03
JP6644678B2 true JP6644678B2 (ja) 2020-02-12

Family

ID=48999089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522480A Expired - Fee Related JP6644678B2 (ja) 2013-06-27 2014-06-25 Ｃｔｌａ−４およびｃｄ４０の両方に特異的に結合可能である二重特異性分子

Country Status (5)

Country Link
US (1) US20170304437A1 (enExample)
EP (1) EP3013859B1 (enExample)
JP (1) JP6644678B2 (enExample)
GB (1) GB201311487D0 (enExample)
WO (1) WO2014207064A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
PL3122781T3 (pl) 2014-03-28 2020-06-15 Xencor, Inc. Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
JP6696982B2 (ja) 2014-11-26 2020-05-20 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
BR112017024770A2 (pt) 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
ES2819870T3 (es) * 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
RU2019102008A (ru) 2016-06-28 2020-07-28 Ксенкор, Инк. Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CN110402255B (zh) * 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
AU2018363922B2 (en) * 2017-11-08 2025-06-12 Kyowa Kirin Co., Ltd. Bispecific antibody which binds to CD40 and EpCAM
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
JP2021508478A (ja) * 2017-12-28 2021-03-11 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ）
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
CA3120875A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
EP3930850A1 (en) 2019-03-01 2022-01-05 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
EP4149632A1 (en) 2020-05-14 2023-03-22 Xencor, Inc. Heterodimeric antibodies that bind msln and cd3
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PT1341909E (pt) 2000-12-12 2005-10-31 Alligator Bioscience Ab Metodo para a evolucao molecular in vitro da funcao de proteina
US6618871B2 (en) 2001-07-24 2003-09-16 Kohler Co. Shower door assembly
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
GB2432366B (en) 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
WO2011030107A1 (en) * 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
EP2796467B1 (en) * 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
US20130295091A1 (en) * 2011-01-10 2013-11-07 University Of Zurich Combination therapy including tumor associated antigen binding antibodies
WO2012123755A1 (en) * 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
RU2657440C2 (ru) * 2011-06-30 2018-06-13 Джензим Корпорейшн Ингибиторы т-клеточной активации
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy

Also Published As

Publication number Publication date
EP3013859B1 (en) 2018-05-30
WO2014207064A1 (en) 2014-12-31
EP3013859A1 (en) 2016-05-04
GB201311487D0 (en) 2013-08-14
JP2016529215A (ja) 2016-09-23
US20170304437A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
EP3013859B1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
KR102926972B1 (ko) Pd-l1 및 cd137에 결합하는 항체 분자
US20210047426A1 (en) Bi-Specific Monovalent Diabodies That are Capable of Binding CD123 and CD3, and Uses Thereof
JP7603205B2 (ja) 抗体分子
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
JP7395471B2 (ja) 改変抗ＳＩＲＰａ抗体及びその使用
KR20230029621A (ko) T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법
EP3988577A1 (en) Anti-cd137 antibodies
AU2017271601A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
KR20140105758A (ko) Ｂｃｍａ 및 ｃｄ에 대한 결합 분자
WO2023045977A1 (zh) 白介素2突变体以及其融合蛋白
CN119264257A (zh) 包含cd137抗原结合位点的fc结合片段
CN111484556A (zh) Bcma和cd3的结合分子
US20250000946A1 (en) Il-2 variants and fusion proteins thereof
TW202221021A (zh) 改良之抗原結合受體
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用
WO2026103838A1 (en) Polypeptide complexes comprising il-21 variants and uses thereof
WO2024199458A1 (en) Il-2 variants with improved stability and compositions thereof
US20250388676A1 (en) Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers
RU2824467C2 (ru) Fc-связывающие фрагменты, содержащие антигенсвязывающий сайт для cd137
HK40073076A (en) Anti-cd137 antibodies
EA051364B1 (ru) Улучшенные антигенсвязывающие рецепторы
HK40088090A (en) Improved antigen binding receptors
HK1225999B (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof
HK1225999A1 (en) Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200108

R150 Certificate of patent or registration of utility model

Ref document number: 6644678

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees